Tag: Paragraph IV certification
30-Month Stay: How Patent Litigation Delays Generic Drug Approval
Explore how the 30-month stay under the Hatch-Waxman Act delays generic drug approval through patent litigation, impacting costs and market access.
View MoreLatest Posts
